Araya Tsgabu Yohannes, Karim Aman, Hailu Gebremedhin Solomon, Periasamy Gomathi, Kahsay Getu
Department of Medicinal Chemistry, School of Pharmacy, Mekelle University, Mekelle, Ethiopia.
Department of Pharmacognosy, School of Pharmacy, Mekelle University, Mekelle, Ethiopia.
Diabetes Metab Syndr Obes. 2021 Mar 15;14:1153-1166. doi: 10.2147/DMSO.S288313. eCollection 2021.
Diabetes mellitus (DM) is a group of metabolic disorders that are characterized by hyperglycemia which results from defects in insulin release or its efficient use by the human body. Although significant progress has been made to manage DM and related complications, it remains a major global health problem. To this end, the search for new antidiabetic drugs from traditionally claimed medicinal plants is important. Baker is an endemic plant used traditionally to treat diabetes in Ethiopia. This study aimed to investigate antidiabetic activity of isolates from the leaf of Baker in streptozotocin-induced diabetic mice.
The exudate of was collected by cutting the leaves and scraping the yellow sap and then dried at room temperature. The dried exudate was subjected to repeated thin layer chromatographic (TLC) separations using a mixture of solvent system to isolate the major compounds identified on the TLC plate. A single dose of streptozotocin (50 mg/kg) was injected intraperitoneally to overnight fasted mice to induce diabetes. Antidiabetic activity of TLC isolates was assessed by methods including oral glucose tolerance test, antihyperglycemic and hypoglycemic activity tests.
Three major isolates were obtained from the TLC analysis of the exudate of . Exudate and TLC isolates were found to be non-toxic up to a dose of 2000 mg/kg. The TLC isolates (Ia and Ib) significantly (p<0.05) reduced blood glucose levels and also increased body weight change of the diabetic mice compared with control groups.
The present study demonstrated the ability of the exudate of and its TLC isolates to significantly decrease blood glucose levels and increase body weights in mice, thus strengthening the claim of its traditional use in DM-related disorders.
糖尿病(DM)是一组代谢紊乱疾病,其特征为高血糖,这是由胰岛素释放缺陷或人体对胰岛素有效利用不足所致。尽管在糖尿病及其相关并发症的管理方面已取得显著进展,但它仍然是一个重大的全球健康问题。为此,从传统药用植物中寻找新型抗糖尿病药物具有重要意义。贝克氏植物是埃塞俄比亚传统上用于治疗糖尿病的本土植物。本研究旨在调查贝克氏植物叶片提取物对链脲佐菌素诱导的糖尿病小鼠的抗糖尿病活性。
通过切割叶片并刮取黄色汁液收集贝克氏植物的渗出物,然后在室温下干燥。将干燥的渗出物使用混合溶剂系统进行反复薄层色谱(TLC)分离,以分离在TLC板上鉴定出的主要化合物。给禁食过夜的小鼠腹腔注射单剂量链脲佐菌素(50 mg/kg)以诱导糖尿病。通过口服葡萄糖耐量试验、降血糖和低血糖活性试验等方法评估TLC分离物的抗糖尿病活性。
从贝克氏植物渗出物的TLC分析中获得了三种主要分离物。发现渗出物和TLC分离物在剂量高达2000 mg/kg时无毒。与对照组相比,TLC分离物(Ia和Ib)显著(p<0.05)降低了糖尿病小鼠的血糖水平,并增加了其体重变化。
本研究证明了贝克氏植物渗出物及其TLC分离物能够显著降低小鼠血糖水平并增加体重,从而强化了其在糖尿病相关疾病传统应用中的说法。